Dapagliflozin/metformin/saxagliptin

Drug Profile

Dapagliflozin/metformin/saxagliptin

Alternative Names: Dapagliflozin/metformin extended release/saxagliptin; Dapagliflozin/saxagliptin/metformin extended release; Metformin extended release/dapagliflozin/saxagliptin; Metformin extended release/saxagliptin/dapagliflozin; Saxagliptin/metformin extended release/dapagliflozin

Latest Information Update: 23 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Adamantanes; Antihyperglycaemics; Azabicyclo compounds; Biguanides; Chlorobenzenes; Dipeptides; Glucosides; Nitriles; Organic bridged compounds; Piperidines; Pyrans; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 03 Aug 2017 AstraZeneca completes a phase I trial in Type-2 diabetes mellitus (In volunteers) in USA (PO) (NCT03169959)
  • 14 Jun 2017 Chemical structure information added
  • 02 Jun 2017 AstraZeneca plans a phase I trial for Type-2 diabetes mellitus in USA (NCT03169959)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top